High-expression of V-domain Imuunoglobulin Suppressor of T-cell Activation (VISTA) Is Correlated with Advanced Pathological Features in Patients with Pancreatic Ductal Adenocarcinoma.


Journal

Iranian journal of allergy, asthma, and immunology
ISSN: 1735-5249
Titre abrégé: Iran J Allergy Asthma Immunol
Pays: Iran
ID NLM: 101146178

Informations de publication

Date de publication:
27 May 2024
Historique:
received: 23 10 2023
accepted: 02 01 2024
medline: 18 10 2024
pubmed: 18 10 2024
entrez: 18 10 2024
Statut: epublish

Résumé

V-domain Imuunoglobulin suppressor of T-cell activation (VISTA) seems a promising immune checkpoint target in cancer treatment; however, its prognostic significance in pancreatic ductal adenocarcinoma (PDAC) remains unknown. Herein, 29 fresh PDAC tissue samples were used to evaluate the mRNA expression level of VISTA by real-time polymerase chain reaction (PCR). Besides, 40 formalin-fixed paraffin-embedded PDAC tissues were collected to evaluate VISTA protein expression by immunohistochemistry. Real-time PCR indicated that high expression of VISTA was significantly correlated with advanced stages of the cancer, based on the tumor/node/metastasis (TNM) stagingand tumor cell differentiation.  Immunohistochemistry results also showed significant correlation of the elevated cytoplasmic expression of VISTA with advanced TNM stages, older age of the patients and was a worsening indicator, regarding the disease-specific survival. In conclusion, we found that the expression levels of VISTA can be a potential prognostic biomarker in PDAC patients and its elevated levels are correlated with poor prognostic outcomes.

Identifiants

pubmed: 39422386
doi: 10.18502/ijaai.v23i3.15636
doi:

Substances chimiques

VSIR protein, human 0
Biomarkers, Tumor 0
B7 Antigens 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

257-271

Auteurs

Hamid Nickho (H)

Immunology Research Center, Institute of Immunology and Infectious Disease, Iran University of Medical Sciences, Tehran, Iran AND Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. hnickho@yahoo.com.

Reza Falak (R)

Immunology Research Center, Institute of Immunology and Infectious Disease, Iran University of Medical Sciences, Tehran, Iran AND Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. rezafalak@yahoo.com.

Fereshteh Rezagholizadeh (F)

Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran AND Cellular and Molecular Research Centre, Iran University of Medical Sciences, Tehran, Iran AND Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran. fereshteh.rgz@gmail.com.

Majid Khoshmirsafa (M)

Immunology Research Center, Institute of Immunology and Infectious Disease, Iran University of Medical Sciences, Tehran, Iran AND Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. mj.khoshmirsafa@hotmail.com.

Mohammad Taghi Joghataei (MT)

Cellular and Molecular Research Centre, Iran University of Medical Sciences, Tehran, Iran AND Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran AND Department of Innovation in Medical Education (DIME), Faculty of Medicine, University of Ottawa, Ottawa, Canada. Mt.joghataei@yahoo.com.

Shabnam Mollazadeh Ghomi (S)

Department of Pathology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran AND Immunology Board for Transplantation and Cell-Based Therapeutics (ImmunoTACT), Universal Scientific Education and Research Network (USERN), Tehran, Iran. Shabnam9091@yahoo.com.

Elaheh Safari (E)

Immunology Research Center, Institute of Immunology and Infectious Disease, Iran University of Medical Sciences, Tehran, Iran AND Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. el.safari@yahoo.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH